

Figure 1: B220+ Lymphoid Cells/Well (X10⁵) vs. Days of Incubation

Legend:

- pre-pro-B and pro-B cells
- ▨ pre-B cells

A. Pro-B-type cultures (Freshly-Harvested Rat BM Lymphoid Cells in Primary Cultures)

Days of Incubation	pre-pro-B and pro-B cells (X10 ⁵)	pre-B cells (X10 ⁵)
0	0.4	2.4
4	1.2	1.0
7	2.1	0.3
11	2.8	0.1
14	3.1	0.2
18	3.8	0.1
21	4.1	0.1

B. Pre-B-type cultures (Freshly-Harvested Rat BM Lymphoid Cells in Primary Cultures)

Days of Incubation	pre-pro-B and pro-B cells (X10 ⁵)	pre-B cells (X10 ⁵)
0	0.5	2.4
4	0.5	2.4
7	0.8	3.0
11	1.5	3.1
14	1.0	3.7
18	0.5	5.5
21	0.1	7.8

C. Pro-B-type cultures (Day 10 Culture-Generated Rat BM Lymphoid Cells in Secondary Cultures)

Days of Incubation	pre-pro-B and pro-B cells (X10 ⁵)	pre-B cells (X10 ⁵)
0	1.0	0.1
4	1.1	0.1
7	1.5	0.1
11	2.3	0.1
14	3.3	0.1
18	3.4	0.2
21	3.6	0.1

D. Pre-B-type cultures (Day 10 Culture-Generated Rat BM Lymphoid Cells in Secondary Cultures)

Days of Incubation	pre-pro-B and pro-B cells (X10 ⁵)	pre-B cells (X10 ⁵)
0	0.8	0.1
4	0.8	0.1
7	1.0	0.6
11	1.3	2.5
14	1.1	3.6
18	0.3	4.8
21	0.1	5.8

Fig. 1




Fig. 2

Relative Increase in Total pre-pro-B Cell Number/Well (X)	Relative Increase in Total pre-pro-B Cell Activity/Well (Y)
0	0.5
2.5	1.5
5.5	3.5
8.5	5.5

Days of Incubation

Fig. 3




Fig. 4

SCANNED, # 22




Fig. 5





Fig. 6


Fig. 7

Non-reducing Reducing

(+/+)CM pre-B (+/+)CM pro-B (-/-)CM pre-B (-/-)CM pro-B (+/+)CM pre-B (+/+)CM pro-B (-/-)CM pre-B (-/-)CM pro-B



Antiserum to PPBSF



Lanes: 1 2 3 4 1 2 3 4

Antiserum to PPBSF

Adsorbed with IL-7

Fig. 10




Fig. 11

Anti-PPBSF Co-F mAb
(clone A4)




Fig. 12

PPBSF cofactor: V V N G I P T Q T N I G W M V S L
Mouse HGF β chain: V V N G I P T Q T T V G W M V S L
Rat HGF β chain: V V N G I P T Q T T V G W M V S L
Human HGF β chain: V V N G I P T R T N I G W M V S L

Fig. 13

Condition	Absorbance 450nm
control medium	0.52
supernatant of HGFβ transfected cells	0.85
Anti-HGFβ Ab	0.52

Fig. 14




Fig. 15

1 2

2230 -

840 -




FIG. 16




FIG. 17

IL-7 (+/+)

IL-7 (-/-)

Fig. 18





Fig. 19





Fig. 20








Fig. 21




Days of rIL-7
Treatment

0


A B220⁺






B B220⁺CD43⁺




C B220⁺CD43⁻



4






7



n.d.




n.d.

9



12

B220



CD43

HSA

slgM

FIG. 22




FIG. 23




FIG. 24

riL-7 (ng/ml)




FIG. 25A




FIG. 25B

FIG. 26




FIG. 26

$$\begin{array}{ccccccc} \varphi_{11} & \varphi_{12} & \varphi_{13} & \varphi_{14} & \varphi_{15} & \varphi_{16} & \varphi_{17} \\ \varphi_{21} & \varphi_{22} & \varphi_{23} & \varphi_{24} & \varphi_{25} & \varphi_{26} & \varphi_{27} \\ \varphi_{31} & \varphi_{32} & \varphi_{33} & \varphi_{34} & \varphi_{35} & \varphi_{36} & \varphi_{37} \\ \varphi_{41} & \varphi_{42} & \varphi_{43} & \varphi_{44} & \varphi_{45} & \varphi_{46} & \varphi_{47} \\ \varphi_{51} & \varphi_{52} & \varphi_{53} & \varphi_{54} & \varphi_{55} & \varphi_{56} & \varphi_{57} \\ \varphi_{61} & \varphi_{62} & \varphi_{63} & \varphi_{64} & \varphi_{65} & \varphi_{66} & \varphi_{67} \\ \varphi_{71} & \varphi_{72} & \varphi_{73} & \varphi_{74} & \varphi_{75} & \varphi_{76} & \varphi_{77} \end{array}$$


Treatment




FIG. 28

Pretreatment




FIG. 29